The Evaluation Of Bone Width Gain Following Split Crest Technique With Or Without Platelet Rich Fibrin( PRF)

The Evaluation Of Bone Width Gain Following Split Crest Technique With Or Without PRF In Conjunction With Simultaneous Implant Placement In Narrow Alveolar Ridges: A Randomized Controlled Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03037125

Enrollment

Registered

2017-01-31

Start date

2017-03-01

Completion date

2019-06-01

Last updated

2024-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ridge Deficiency

Brief summary

Split crest technique is a technique for horizontal bone augmentation used in case of narrow alveolar ridges as an alternative to the more aggressive techniques such as onlay bone grafting, guided bone regeneration (GBR) and distraction osteogenesis The study goal is to evaluate whether if there will be any benefit of using platelet rich fibrin (PRF) with the split crest technique regarding bone width gain and healing response in comparison with split crest technique alone, where PRF is considered an autologous, growth factor containing material which is easy to collect and is of low cost.

Interventions

PROCEDURESplit Crest with PRF

Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap

PROCEDURESplit Crest without PRF

Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients with at least one missing tooth in the maxillary region 2. All the selected patients have a bucco-palatal width of the edentulous alveolar ridge from 3.5-5.5mm. 3. All the selected patients have at least 12 mm residual bone height at the edentulous area 4. The recipient site of the implant should be free from any pathological conditions. 5. No diagnosed bone disease or medication known to affect bone metabolism. 6. Patients who are cooperative, motivated, and hygiene conscious.

Exclusion criteria

1. Patients unable to undergo minor oral surgical procedures. 2. Patients with a history of drug abuse or catabolic drugs. 3. Patients with a history of psychiatric disorder. 4. Patients with unrealistic expectations about the esthetic outcome of implant therapy. 5. Patients with insufficient vertical inter-arch space, upon centric occlusion, to accommodate the available restorative components. 6. Patients in the growth stage with partially erupted teeth. 7. Patients who have any systemic condition that may contraindicate implant therapy. 8. Patients who have any habits that might jeopardize the osseointegration process, such as smoking and alcoholism. 9. Patients with parafunctional habits that produce overload on the implant, such as bruxism and clenching.

Design outcomes

Primary

Measure	Time frame
Bone width gain	6 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026